Dimensional Fund Advisors LP Lowers Holdings in Glaukos Corporation $GKOS

Dimensional Fund Advisors LP trimmed its stake in Glaukos Corporation (NYSE:GKOS) by 3.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 199,084 shares of the medical instruments supplier’s stock after selling 6,377 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Glaukos were worth $21,426,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. First Horizon Corp increased its holdings in shares of Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Glaukos in the 4th quarter worth about $28,000. Larson Financial Group LLC grew its position in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. Parallel Advisors LLC increased its stake in Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 215 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on GKOS shares. Truist Financial increased their price target on shares of Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. HC Wainwright upped their price objective on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. increased their target price on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $177.33.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $170.88 on Friday. The firm’s 50-day moving average price is $142.71 and its 200-day moving average price is $126.82. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. The company has a market cap of $10.08 billion, a PE ratio of -52.58 and a beta of 0.78. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $184.00.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business’s revenue for the quarter was up 49.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.24) earnings per share. As a group, analysts anticipate that Glaukos Corporation will post -0.35 EPS for the current year.

Insider Buying and Selling

In other Glaukos news, Director Leana Wen sold 525 shares of Glaukos stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director owned 21,092 shares of the company’s stock, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the sale, the chief financial officer owned 43,906 shares of the company’s stock, valued at approximately $7,024,960. This represents a 18.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 40,525 shares of company stock worth $6,116,806. 5.90% of the stock is owned by insiders.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.